VC View: Deal-Making During A Pandemic And 2021 Expectations

Interview With Naseem Amin And Christian Schetter

In the latest instalment of VC Playbook, In Vivo gets to know Arix Bioscience, a relatively young venture capital firm that went public in 2016. Arix has “has many similarities yet some key differences from a typical venture capital firm,” says the management team.

Arix Bioscience is focused on investing in biotech companies, but the VC has a wide footprint. Looking at Arix’s historic investments, there is a greater concentration in the US than one would expect from a venture capital firm headquartered in London, UK. Although Arix is a newer player in the biotech investment arena, its portfolio includes companies that are transitioning through the development life cycle.

“We have had four companies in the public portfolio, – companies that have gone through the IPO process – and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Neuromodulation Is Booming – But Shocks Could Still Come

Oct 22 2025

• By Barnaby Pickering

The neuromodulation space is quickly filling with well-funded companies that have demonstrated early signs of success. However, with strategics seemingly unwilling to spend on novel technologies and pharma desperate to maintain its foothold in CNS, these companies will face many challenges.

Deals In Depth: September 2025

Oct 13 2025

• By Deanna Kamienski and Maureen Riordan

Eight $1bn+ alliances were penned in September, and four exceeded $2bn. In the top alliance by deal value, Monte Rosa Therapeutics will apply its AI-enabled QuEEN platform for the discovery and development of novel molecular glue degraders for immune-mediated diseases.

ALS Drug Development Case Studies: MediciNova And Coya Therapeutics

Oct 08 2025

• By David Wild

MediciNova and Coya Therapeutics are advancing ALS candidates as regulatory flexibility and Phase II pipeline concentration create a pivotal market inflection point.

US Tariffs And Geopolitical Tensions Push EU To New Trade Routes And Infrastructure Growth

Oct 06 2025

• By Francesca Bruce

The EU is diversifying its trading partners, which means that new markets may open up to the pharmaceutical industry, countering transatlantic tensions.

China’s Medtech Policies Prompt Reflection Among Global Companies As Local Players Adapt

Oct 20 2025

• By Ashley Yeo

Chinese medtechs are expanding rapidly worldwide, but gaining market access within China itself – poised to become the world’s largest medtech market – is proving to be a very different challenge.